Opendata, web and dolomites

ASPIVIX

Vacuum Medical Device for Safe and Gentle Cervix Grasping Gynecological Applications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ASPIVIX project word cloud

Explore the words cloud of the ASPIVIX project. It provides you a very rough idea of what is the project "ASPIVIX" about.

intervention    contamination    intended    pain    projected    single    cervix    risk    painful    sales       asian    gynecologist    cumulative    economic    cross    besides    pulling    adoption    care    350m    firm    unintended    procedure    gynecologists       curettage    invested    trigger    nearly    unchanged    benefit    10    generate    iucd    female    uterus    sized    representing    grow    aspivix    roi    patients    replace    women    6m    uterine    tenaculum    lesions    yearly    return    featured    disadvantages    patented    euros    29    disruptive    american    2021    mills    north    social    85    traumatic    reduce    market    inside    worldwide    eradicates    fulfill    28    bleeding    22m    physician    exploration    insertions    proved    reduces    billions    forceps    considering    infection    thanks    shorten    device    traction    units    prevents    for    refrain    vaginal    total    cavity    grasping    gynecological    64    instead    demand       poor    practices    exacerbates    contraceptive    indications    gentle    cagr2016    revenues    investment    84    markets    pregnancies    valued   

Project "ASPIVIX" data sheet

The following table provides information about the project.

Coordinator
ASPIVIX SA 

Organization address
address: CHEMIN DE RENENS 2 BIS
city: LAUSANNE
postcode: 1004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.aspivix.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASPIVIX SA CH (LAUSANNE) coordinator 50˙000.00

Map

 Project objective

For years, gynecologist practices related to Intra-Uterine Contraceptive Device (IUCD) insertions, curettage and several other common indications, have featured poor care and low attention to female patients.
The use of the Tenaculum, grasping and pulling on the cervix, inside the vaginal cavity, proved to be painful and traumatic for 84% of the women, and eventually to trigger lesions and bleeding in 29% of the patients, as well as cross-contamination in 5-10% of the women. These disadvantages refrain the use of IUCD contraceptive which exacerbates the unintended pregnancies, sized yearly in 85 mills and representing billions of euros in social costs worldwide. In response, we have developed Aspivix, a new disruptive gynecological device that reduces the pain and eradicates the bleeding during the exploration procedure. Our patented device will replace the Tenaculum forceps, unchanged for over 100 years, to provide gynecologists an easy-to-use device where gentle and firm cervix uterus grasping and traction is needed. Thus, our device will facilitate the adoption of IUCD, which could avoid up to 8% of unintended pregnancies and reduce derived social costs. Besides, Aspivix is intended for a single use which prevents the risk of contamination and cross-infection. Overall, Aspivix has the potential to shorten the intervention procedure (2 steps instead 7), which will represent for the physician a 28% economic benefit. As result, Aspivix will fulfill the needs of more than 64 M of women worldwide/year, a market that is projected to grow at a CAGR2016-2021 of ~6.5% due to the high demand of IUCD insertions and is valued in more than €350M. In this way, thanks to the sales of 22M units in the European, Asian and North American Markets after 5-years, Aspivix will generate cumulative revenues of nearly €80 M and, considering the total investment of €3.6M, a return of investment (ROI) of €8.3 per euro invested.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ASPIVIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ASPIVIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More